Topiramate
Product Images NDC 70934-606

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70934-606). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (70934 606 30 Master Bottle Label Approval Rev A 03 20)

Topiramate Tablets USP 50 mg bottle label from Denton Pharma, Inc. dba Northwind Pharmaceuticals. The label states the package contains 30 tablets, prescription only, with storage instructions at 20°-25°C (68°-77°F) in original container, protecting from moisture. Additional co-packaged inserts and manufacturing information are visible on the label.*

FDA Label Image

Structured Product Formula For Topiramate (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 01)

Chemical structure of the active ingredient topiramate, showing its molecular arrangement including oxygen, sulfur, nitrogen, and carbon groups with stereochemistry indicated, as submitted by Denton Pharma, Inc. dba Northwind Pharmaceuticals.*

FDA Label Image

Structured Product Formula For Topiramate (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 02)

A cumulative incidence curve showing rates for time to first seizure over approximately 500 days. Two lines represent topiramate dosages: 50 mg/day (solid line) and 400 mg/day (dashed line), with respective sample sizes noted. The curve tracks cumulative seizure occurrence over time with a statistical significance indicator (P = 0.0002).*

FDA Label Image

Topiramate Tablets Usp (Dc0a034e Df8a 4de6 Be65 82ebf72ddb48 03)

A bar chart showing change from baseline to double-blind phase in average monthly migraine period rate with standard error for placebo and three dosages of topiramate (50 mg/day, 100 mg/day, 200 mg/day) across two studies (Study 11 and Study 12). Results indicate dose-dependent reduction in migraine rates with statistical significance noted for 100 mg/day and 200 mg/day doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.